Accordingly, tumor-infiltrated CD8+ T and NK cells, especially those with effector phenotypes (granzyme B and CD25) in mice treated with αNKG2A-N215 were significantly more numerous than those in mice treated with the combination therapy of αNKG2A and N215 (Figures 5 and 6). The gene discussed is GZMB; the disease is neoplasm.